Healthcare provider profile · identity verified

Aaron John Krohn, MD

Internal Medicine · TACOMA, WA · NPI 1750493722

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	554	139
Amlodipine Besylate	Amlodipine Besylate	373	102
Losartan Potassium	Losartan Potassium	313	91
Lisinopril	Lisinopril	264	68
Metoprolol Succinate	Metoprolol Succinate	230	60
Rosuvastatin Calcium	Rosuvastatin Calcium	230	68
Levothyroxine Sodium	Levothyroxine Sodium	221	56
Omeprazole	Omeprazole	173	52
Hydrochlorothiazide	Hydrochlorothiazide	169	50
Gabapentin	Gabapentin	146	40
Furosemide	Furosemide	131	43
Tamsulosin Hcl	Tamsulosin Hcl	131	36
Eliquis	Apixaban	129	31
Pantoprazole Sodium	Pantoprazole Sodium	116	35
Carvedilol	Carvedilol	110	25
Metformin Hcl	Metformin Hcl	109	34
Metformin Hcl Er	Metformin Hcl	103	30
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	100	24
Escitalopram Oxalate	Escitalopram Oxalate	94	29
Duloxetine Hcl	Duloxetine Hcl	83	23
Spironolactone	Spironolactone	77	24
Meloxicam	Meloxicam	76	29
Sertraline Hcl	Sertraline Hcl	75	19
Tramadol Hcl	Tramadol Hcl	74	11
Potassium Chloride	Potassium Chloride	73	21
Pravastatin Sodium	Pravastatin Sodium	63	18
Trazodone Hcl	Trazodone Hcl	58	14
Methocarbamol	Methocarbamol	54	17
Finasteride	Finasteride	53	14
Metoprolol Tartrate	Metoprolol Tartrate	52	15
Clopidogrel	Clopidogrel Bisulfate	51	suppressed
Lorazepam	Lorazepam	51	19
Zolpidem Tartrate	Zolpidem Tartrate	48	11
Ezetimibe	Ezetimibe	47	15
Venlafaxine Hcl Er	Venlafaxine Hcl	44	suppressed
Bupropion Xl	Bupropion Hcl	43	11
Allopurinol	Allopurinol	42	13
Albuterol Sulfate Hfa	Albuterol Sulfate	41	21
Famotidine	Famotidine	40	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	40	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	40	15
Fluticasone Propionate	Fluticasone Propionate	39	21
Simvastatin	Simvastatin	39	11
Mirtazapine	Mirtazapine	38	suppressed
Xarelto	Rivaroxaban	37	suppressed
Ozempic	Semaglutide	36	11
Quetiapine Fumarate	Quetiapine Fumarate	35	suppressed
Alendronate Sodium	Alendronate Sodium	34	11
Baclofen	Baclofen	33	suppressed
Montelukast Sodium	Montelukast Sodium	33	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	33	23
Alprazolam	Alprazolam	32	15
Citalopram Hbr	Citalopram Hydrobromide	32	suppressed
Oxycodone Hcl	Oxycodone Hcl	32	suppressed
Prednisone	Prednisone	32	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	32	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	31	suppressed
Glipizide	Glipizide	31	suppressed
Acyclovir	Acyclovir	29	14
Buspirone Hcl	Buspirone Hcl	29	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	29	11
Tizanidine Hcl	Tizanidine Hcl	29	13
Clonazepam	Clonazepam	28	suppressed
Hydralazine Hcl	Hydralazine Hcl	28	suppressed
Myrbetriq	Mirabegron	28	suppressed
Bupropion Hcl Sr	Bupropion Hcl	27	suppressed
Synthroid	Levothyroxine Sodium	26	suppressed
Jardiance	Empagliflozin	25	suppressed
Valacyclovir	Valacyclovir Hcl	24	11
Atenolol	Atenolol	23	suppressed
Loperamide	Loperamide Hcl	23	suppressed
Trulicity	Dulaglutide	22	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	20	suppressed
Diclofenac Sodium	Diclofenac Sodium	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	20	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	19	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Ipratropium Bromide	Ipratropium Bromide	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Enalapril Maleate	Enalapril Maleate	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Rizatriptan	Rizatriptan Benzoate	16	suppressed
Eplerenone	Eplerenone	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Glimepiride	Glimepiride	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Nystatin	Nystatin	14	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	13	suppressed
Alvesco	Ciclesonide	13	suppressed
Clobetasol Propionate	Clobetasol Propionate	13	suppressed
Creon	Lipase/Protease/Amylase	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Nitroglycerin	Nitroglycerin	13	11
Ondansetron Odt	Ondansetron	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Azithromycin	Azithromycin	12	12
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Felodipine Er	Felodipine	12	suppressed
Gemtesa	Vibegron	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	11	suppressed
Dexlansoprazole Dr	Dexlansoprazole	11	suppressed
Doxepin Hcl	Doxepin Hcl	11	suppressed
Levemir Flexpen	Insulin Detemir	11	suppressed
Mesalamine Er	Mesalamine	11	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error